News

- Trial led to FDA-approved expansion of the use of Gilenya to include children 10 years or older with relapsing MS
 
Results from a phase 3 clinical trial comparing Gilenya® (fingolimod, Novartis AG) and Avonex® (interferon beta-1a, Biogen) in children and teens with relapsing MS have been published in the September 13, 2018 issue of The New England Journal of Medicine. Gilenya reduced relapse rates by 82% over two years, compared to treatment with Avonex, and significantly reduced the rate of new or enlarging MS lesions shown on MRI. The side effects during the trial were similar to what have been seen in the adult population. Information on potential adverse events is outlined in the prescribing information and Medication Guide for patients and families.
 
The results of the published study led to the May 2018 approval by the U.S. Food and Drug Administration that expanded the use of Gilenya to include the treatment of children and adolescents 10 years of age or older with relapsing MS. This was the first disease-modifying therapy specifically approved for pediatric MS. The National MS Society’s early and fundamental work creating consistency around the diagnosis and care of children with MS helped lay the groundwork for this major milestone.
 
Read announcement about FDA’s approval of Gilenya for children with relapsing MS
 
Read the scientific abstract of the published paper in The New England Journal of Medicine